Abstract：Objective To study the effects of erythropoietin (EPO) on serum levels of neuron-specific enolase (NSE) and S-100B in neonates with hypoxic-ischemic encephalopathy (HIE) and the underlying mechanism. Methods Forty neonates with HIE were randomly divided into conventional treatment (n=20) and EPO treatment groups (n=20). Twenty healthy full-term neonates born during the same period were randomly selected as the normal control group. The conventional treatment group received conventional treatment, while the EPO treatment group received conventional treatment as well as EPO [200 IU/(kg·d)] which was given by intravenous infusion from the second day after birth. The course of treatment was 7 days. Blood samples of the three groups were collected on the first day after birth (before treatment) and the ninth day after birth (after treatment). Serum levels of NSE and S-100B were measured by doubleantibody sandwich ABC-ELISA. Results Before treatment, the two treatment groups had significantly higher serum NSE and S-100B levels than the normal control group (PP>0.05). The serum NSE and S-100B levels on the ninth day after birth were significantly lower than those on the first day after birth in the three groups (PPConclusions Dynamic monitoring of serum NSE and S-100B levels may be helpful for the early diagnosis of HIE and the assessment of brain injury repair in newborns with HIE. EPO may be helpful for the repair of neurons and glial cells.
PEI Xue-Mei,GAO Ran,ZHANG Guo-Ying et al. Effects of erythropoietin on serum NSE and S-100B levels in neonates with hypoxicischemic encephalopathy[J]. CJCP, 2014, 16(7): 705-708.
Kumral A, Tuzun F, Oner MG, et al. Erythropoietin in neonatal brain protection: the past, the present and the future[J]. Brain Dev, 2011, 33(8): 632-643.
Tiainen M, Roine RO, Pettila V, et al. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia[J]. Stroke, 2003, 34(12): 2881-2886.
Celtik C, Acunas B, Oner N, et al. Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy[J]. Brain Dev, 2004, 26(6): 398-402.
[9]
Nygaard O, Langbakk B, Romner B. Age-and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder[J]. Clin Chem, 1997, 43(3): 541-543.
[10]
Muller B, Evangelopoulos DS, Bias K, et al. Can S-100B serum protein help to save cranial CT resources in a peripheral trauma centre? A study and consensus paper[J]. Emerg Med J, 2011, 28(11): 938-940.
[11]
Wojtczak-Soska K, Lelonek M. S-100B protein: An early prognostic marker after cardiac arrest[J]. Cardiol J, 2010, 17(5): 532-536.
[12]
Xiong T, Qu Y, Mu D, et al. Erythropoietin for neonatal brain injury: opportunity and challenge[J]. International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience, 2011, 29(6): 583-591.
[13]
Zhou TF, Yu JG.Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia[J]. J Surg Res, 2013, 183(1): 304-312.
Bendix I, Schulze C, Cv H, et al. Erythropoietin modulates autophagy signaling in the developing rat brain in an in vivo model of oxygen-toxicity[J]. Int J Mol Sci, 2012, 13(10): 12939-12951.
[16]
Fan X,van Bel F, Kooij MA, et al. Hypothermia and erythropoietin for neuroprotection after neonatal brain damage[J]. Pediatr Res, 2013, 73(1): 18-23.
[17]
Fang AY, Gonzalez FF, Sheldon RA, et al. Effects of combination therapy using hypothermia and erythropoietin in a rat model of neonatal hypoxia-ischemia[J]. Pediatr Res, 2013, 73(1): 12-17.
